Actively Recruiting
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
Led by First Affiliated Hospital of Zhejiang University · Updated on 2026-03-02
404
Participants Needed
1
Research Sites
97 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.
CONDITIONS
Official Title
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years inclusive
- Diagnosis of a hematological disease requiring hematopoietic stem cell transplantation
- Expected platelet count 64; 10 x 10�B9/L persisting for 5 days or more
- Normal coagulation function
- Adequate organ function: AST and ALT 64; 3 times the Upper Limit of Normal, Total Bilirubin 64; 2 times Upper Limit of Normal; Serum Creatinine 64; 2 times Upper Limit of Normal; Creatinine Clearance 50 mL/min by Cockcroft-Gault formula; Left Ventricular Ejection Fraction 50% measured by Echocardiography
- Voluntary signed informed consent with ability to understand and comply with study requirements
You will not qualify if you...
- Diagnosis of acute promyelocytic leukemia
- Pregnant or breastfeeding women, or women of childbearing potential unwilling to use effective contraception
- Presence of active bleeding or infection
- History of primary immune thrombocytopenia or hemolytic uremic syndrome
- Known hereditary or acquired hemorrhagic disorders
- Receiving anticoagulant or antiplatelet therapy
- Severe cardiac insufficiency (EF < 60%) or severe arrhythmias including significant QTc prolongation, ventricular tachycardia, atrial fibrillation, second-degree heart block, recent myocardial infarction, or symptomatic coronary artery disease
- Severe liver impairment (ALT, TBIL > 3 times Upper Limit of Normal)
- Severe pulmonary insufficiency
- Severe renal insufficiency (Creatinine > 2 times Upper Limit of Normal or creatinine clearance < 50 ml/min)
- Mental disorders or conditions preventing informed consent and study compliance
- Other investigator-determined reasons for ineligibility
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
Y
Yi Luo
CONTACT
L
Luxin Yang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here